News Of The Day
|
News Of The Day
Check Out The Blog Updated Daily; HCV In The News DDW 2013 - May 18-21, 2013 - Orlando, FL Digestive Disease Week - The conference will showcase the latest advances in GI research, medicine and technology in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery View Media and DDW Updates EASL - News Updates Continue.... May 23 Harvard Presents - A New Era in the Management of Chronic Hepatitis C The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments Sixty Percent of Surveyed Physicians Agree That They Are Beginning To Warehouse HCV Patients Until New Interferon-Free Regimens Are Available, According to a Recently Published BioTrends Report May 22 Updated- HCV Treat Now Or Wait A collection of research articles weighing the risks and benefits of treating HCV now vs waiting for future therapies. Interferon-free, treat-all approach cost effective, beneficial for chronic HCV Gilead steals a march for hepatitis C drug application May 21 European Medicines Agency Validates Gilead's Marketing Application for Sofosbuvir for the Treatment of Hepatitis C DDW 2013 Video - Simeprevir (Tmc435) Plus Sofosbuvir (Gs-7977) With or Without Ribavirin HCV GT 1 Null Responders. DDW 2013 - Janssen's Simeprevir Phase 3 PROMISE Study demonstrating (SVR12) in 79 percent of patients DDW: An Analysis of Response Rates by Fibrosis Stage in Patients Treated With Faldaprevir, BI 207127, and Ribavirin in the SOUND-C2 Study Experts review NAFLD treatment options May 18 NATAP - Summary EASL 2013 - New HCV DAAs on their way soon: what do the phase III studies tell us? Current and Future Therapies for Hepatitis C Virus Infection If the past is a harbinger of the future, therapy for HCV infection will probably continue to advance at a brisk pace. Many additional potent agents are in the clinical pipeline, and interferon-free regimens are likely to dominate the HCV therapeutic landscape within the next 5 years..... Hepatitis C in the United States Perspective Care for hepatitis C is evolving rapidly, with increasingly effective and better-tolerated antiviral therapies being evaluated and approved for use. It's clear, however, that not everyone who would qualify for therapy has been tested and identified, referred for appropriate care, and offered or given the best therapy available. Furthermore, currently used antiviral drugs - pegylated interferon and ribavirin "base" plus either telaprevir or boceprevir - can cost more than $70,000 for a full course of therapy. It is expected that the new oral antiviral agents will be just as expensive, at least in the short term. May 16 Depression: Hep C Treatment Side Effects and Help to Get Through It, Part 1 Depression; Hep C Treatment Side Effect and Help to Get Through It, part 2. May 17 Organ donor cards hard to implement in China and China's unethical practice of organ harvesting To understand the importance of today's news from China to implement consent for organ transplants or donor cards, the public may need some background on China's unethical practice of organ harvesting from imprisoned Falun Gong practitioners As Hepatitis C Spreads, Scotland Steps In Minn. DOH recommend one-time Hepatitis-C shots for Baby Boomers Stop paid blood donor clinics in Toronto, victims say May 15 Watch - Best of the EASL 2013 on hepatitis C - webcast with Dr Andrew Muir Hepatitis C Therapy Update 2013-What About Interferon-free Regimens? Interferon-free regimens are widely being tested in clinical trials with encouraging results. The following selected trials demonstrate how rapidly progress is being made. Beginning in 2010, studies demonstrated the potential for antiviral efficacy of an all-oral regimen using combinations of drugs with different targets. Report highlights major failings in UK response to hepatitis C The UK needs to “be doing so much more” in response to hepatitis C, according to a new report. Supported by a consortium of leading hepatitis C charities BLOG: One in four Massachusetts physicians received gifts, industry payments According to a recent report in The New England Journal of Medicine, one in four physicians in Massachusetts received at least one gift or payment from pharmaceutical or medical device companies valued at $50 or more since the commonwealth began tracking these payments in July 2010 . May 14 Is There a Future for Milk Thistle In HCV? Research, a few studies which offer a better understanding of the popular supplement, including the possible benefits. May 13 U.S. FDA grants priority review to Simeprevir (TMC435) for combination treatment of genotype 1 chronic hepatitis C Janssen Research & Development, LLC (Janssen) announced today that the FDA has granted Priority Review to the New Drug Application (NDA) for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease. Drug-Induced Liver Injury in Elderly Patients Differs From Younger Patients Spring Hepatitis Newsletters- Waiting for Approval of Drugs... What About Herbal Supplements? May 6 AbbVie's Investigational Hepatitis C Virus Regimen Gets Breakthrough-Therapy Designation AbbVie’s investigational direct-acting antiviral (DAA) combination regimen with and without ribavirin for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA). ABT-450, Enanta’s lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, is one of three DAAs in the regimen. Boceprevir/peginterferon/ribavirin effective, safe in chronic HCV patients with compensated cirrhosis May 2 Gilead Sofosbuvir and ledipasvir: Plans to initiate a third Phase 3 clinical trial with and without ribavirin Surveyed Gastroenterologists Agree - Gilead's interferon-free regimen has Advantages Over Current Hepatitis C Therapies EASL 2013 - Internet Symposium: Watch Advances in Chronic Hepatitis C Management and Treatment 2013 : HCV News Digest |
EASL 2013 The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), will take place April 24 to 28 in Amsterdam, EASL Links Blog- News Updates Tips For Viewing Hepatitis C Abstracts EASL Website EASL Abstract Search Click here for a downloadable PDF version of the Abstract Book. EASL 2013 - Internet Symposium: Watch Advances in Chronic Hepatitis C Management and Treatment Quick Links - New Data- Hepatitis C Investigational Drugs AbbVie is a new, independent biopharmaceutical company composed of Abbott’s former proprietary pharmaceutical business ABT-267, ABT-333-non- nucleoside, ABT-450/r r = ritonavir May 6 Update AbbVie's Investigational Hepatitis C Virus Regimen Gets Breakthrough-Therapy Designation Achillion ACH-3102 Sovaprevir (ACH-3102) Boehringer Ingelheim Faldaprevir/ (BI 201335), Bristol-Myers Squibb Daclatasvir/asunaprevir/BMS-791325, Gilead Sofosbuvir (GS-7977) Ledipasvir (GS-5885) Idenix IDX719 Janssen Simeprevir (TMC435) Merck MK-5172 Daclatasvir MK-5172 and Daclatasvir MK-5172 and Daclatasvir-Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Victrelis Vertex ALS-2200 (VX-135) Incivek EASL - News Updates A Few Quick Links - News Updates News/Incivek (Telaprevir) News/Victrelis (Boceprevir) HCV Triple-therapy Side Effects Side Effects- Exploratory Interferon Free Therapies Interferon Free Combinations Sofosbuvir (GS-7977 and PSI-7977) News/Fibrosis News/Cirrhosis News/Transplant News/Liver Cancer Of Interest Lucinda K. Porter, RN Personal Experience - Starting 12 weeks of sofosbuvir, GS-5885, and ribavirin Coming in September 2013 A second book authored by Lucinda K. Porter, RN Hepatitis C Treatment One Step at a Time: Inspirational Readings and Practical Tips for Successful Hepatitis C Treatment First Book FREE FROM HEPATITIS C Telaprevir and Boceprevir Pocket Guide For UsingTelaprevir and Boceprevir Telaprevir/INCIVEK Prescribing Information for INCIVEK including the Medication Guide. Boceprevir/Victrelis Prescribing Information and Medication Guide Patient Assistance Programs INCIVEK/Telaprevir and VICTRELIS (Boceprevir) Patient Assistance Program Hepatitis C Pipeline Feb 20 2013- EASL-Burden of Liver Disease in Europe: Looks at leading causes of cirrhosis and primary liver cancer in Europe Need To Talk To Someone ? Help is available, recently "Project Inform" announced the launch of a new national helpline, 877-HELP-4-HEP (877-435-7443), run by and for people affected by hepatitis C. The helpline operates Monday through Friday 9am to 7pm EST. To learn more, visit www.help4hep.org email info@help4hep.org. New ALF Website The Hepatitis C: Diagnosis, Treatment, Support website 1-800-GOLIVER (1-800-465-4837) In addition, questions sent on e-mail to info@liverfoundation.org will be promptly answered. Hepatitis C Newsletters
HCV Advocate Newsletter The HCV Advocate newsletter is a valuable resource designed to provide the hepatitis C community with monthly updates on events, clinical research, and education HBV Advocate HBV Journal Review HepCBC Online monthly newsletter GI & Hepatology News is the official newspaper of the AGA Institute and provides the gastroenterologist with timely and relevant news and commentary about clinical developments and about the impact of health-care policy. The newspaper is led by an internationally renowned board of editors. Hep Magazine Newsletter Signup for Hep's email newsletter and keep with the latest info to help keep your liver healthy. http://lists.smartandstrong.com/?p=subscribe&id=13 Hepatitis C Victoria publishes two regular e-newsletters: Liver Spot, for people interested in general hepatitis news and views, and Viral Lowdown, for people working in and around the field of hepatitis C, as well as an electronic version of Good Liver, our quarterly magazine.You can sign up for any of these HERE. Hepatitis C Trust Newsletter Published every spring and winter. CAP Hepatitis C Literature Review Monthly Pubmed Review of the most relevant research on hepatitis C. Mailing Lists Subscribe to the NATAP HCV Mailing List email: nataphcv-request@natap.org *with a subject line of subscribe Learn more here HEPC-List The list continues to be a great source of support/information and can be joined by clicking here Magazine & Books Free from Hepatitis C:Your Complete Guide to Healing Hepatitis C Lucinda K. Porter, RN, author of Free from Hepatitis C, is a hepatitis C patient, nurse and recognized expert in the hepatitis C field. Lucinda was a clinical research nurse at Stanford University Medical Center’s Hepatology division. In 1998, she co-founded the Redwood City Hepatitis C Support Group. She has been a guest speaker, educator and consultant, particularly on the subject of hepatitis C. Lucinda is actively engaged in community awareness activities focusing on issues surrounding viral hepatitis. Learn More Here Hepatitis C No Longer a Lifelong Illness Leading hepatologist and hepatitis C expert Gregory Everson, M.D. provides state-of-the-science information in "Curing Hepatitis C" -- a new book that outlines the latest treatment protocols that offer the outcome of complete cure from this disease Hepatitis C Choices Free Online Book Important link if you are considering the new therapies. Be sure to talk with your doctor about all of your other medications prior to taking any prescription. Hep C Magazine Hepatitis NSW publishes two magazines: The Hep Review: is a 60 page magazine that comes out every three months, containing news, info, opinion, research and feature articles about hepatitis. Transmission Magazine: is a 16 page magazine that comes out every three months and is targeted at people affected by hep C or at risk of contracting it, and who prefer less text and more artwork. We strive to provide high quality magazines and content developed by us is produced according to our resources development guidelines. Where relevant, we provide author and source details. Each magazine is produced under the guidance of editorial committees made up of people from the hepatitis and related sectors, and people recruited for their experience in journalism and desktop publishing. Both our magazines aim to provide you with up-to-date information. They also give you the opportunity to provide input through telling your story, suggesting ideas for the articles that we write and helping with production (proofreading, mailouts, etc.) In this part of our website you will find: Hep Review magazine Hep Review index Hep Review promo campaign Transmission Magazine Email Alert FDA Hepatitis List Serve This e-mail list provides updates on safety and regulatory issues related to hepatitis B and C products (labeling changes, safety warnings, product approvals). Intended for patients, industry, academia, government agencies, and other interested parties. To sign up, click on link above. New Resource New Digital Liver Disease Journal - "Clinical Liver Disease" This journal is an official digital educational resource from the American Association for the Study of Liver Diseases. Visitors are able to view videos, full data, and download files in either HTML or PDF formats Hepatitis C Support Forums HCV Support HEPCnet Forums Med Help HepC Nomads Forum Hepatitis C Kids Support Forum Daily Strength Hepatitis C Support Hepatitis Central Hep C Friends Cirrhosis/ESLD Support The Liver Failure Support Group Transplant buddies |